Breast cancer is a major health problem for Iranian women. Considering the costs of prevention, diagnosis, and treatment of BC, its management imposes a heavy burden on the economy of the household, which increases significantly with the advanced stages of the disease. The findings of our study showed that the contribution of OOP by patients to the total direct and indirect medical expenses was 32.89%. Therefore, many households are faced with impoverishment or catastrophic expenditure by paying these costs.
A significant portion OOP costs is associated with drug expenses. The study found that 47.18% of OOP costs are attributed to drug expenses, 16.19% to laboratory costs, 11.74% to imaging costs, 11.20% to visit costs, 8.40% to hospitalization costs, 2.84% to doctor's services costs, and 2.45% to physiotherapy costs. The results of Parnian et al.'s study showed that the average OOP payment including the cost of the drug with a rate of $37.99 ± 45.31 was the highest direct medical cost (
19). A study conducted in India revealed that direct medical costs represented 56.3% of the total out-of-pocket expenses. Within the direct medical costs, systemic treatment accounted for 19.7%, radiotherapy for 12.97%, and surgical costs for 9.71%. Approximately 74.4% of patients availed government financial assistance, while 8% received full reimbursement (
20). A study in Saudi Arabia showed that drug costs included 67% of the total medication costs. Of these costs, trastuzumab alone accounts for 94% (
21). In Iran, as in other countries, drug costs constitute the largest share of cancer treatment costs. During the past years, due to international sanctions and the rise of the currency, the government has tried to cover a part of these costs, but the patients still pay a large part of the costs in the form of OOP.
BC affects the quality and quantity of life, as well as the economic well-being of affected patients and their families. The results of this study showed that with increasing income, patients had more OOP. Panahi et al.'s study showed that income has a positive and significant effect on OOP expenses (
22). Pisu et al.'s study showed that the lower income of patients is effective in increasing OOP costs and OOP burden (
23). It can be analyzed that patients with higher income are more referred to private hospitals, and tend to pay more OOP.
This study demonstrated that the out-of-pocket costs decreased as patients age. This could be attributed to younger or middle-aged patients having higher life expectancies and being more willing to pay for their treatment. Pisu et al.'s study showed that younger age is effective in increasing OOP costs and OOP burden (
23). A study by Bygrave et al. in 2021 showed that patients with younger age (≤ 65 years) are at increased risk of having financial problems due to OOP costs (
24). Compared to younger patients with BC, older patients were shown to incur lower costs (
25). Another study showed that costs of care decreased with increasing age at most stages of BC diagnosis (
26). These findings indicate that older patients receive less treatment.
The results of this study showed that people who were covered by support institutions had less OOP payments, but it had no significant effect on patients' OOP payments (P < 0.05). Pisu et al.'s study showed that the use of supportive services is effective in increasing OOP costs and OOP burden (
23).
People who live in rural areas are more vulnerable to BC than people who live in urban areas, according to their income level. For this reason, they are mostly covered by a social support organization. The results of our study showed that people living in rural areas have lower OOP costs. Due to the fact that the willingness to pay is less in rural areas, another reason is that follow-up treatment and access to private hospitals and private doctors' offices are less in rural areas. Additionally, most people living in rural areas were covered by a social support organization. Other studies have shown that younger and lower-income rural patients were most burdened by breast cancer costs.
Prevention and early detection play an important role in reducing BC costs. A study showed that early detection and targeted treatment of cancer can save up to 11.35% of total cancer costs (
27). Breast cancer is usually diagnosed in late stages in countries with limited resources. Early detection can shorten the stage of diagnosis, potentially improve the chances of survival and cure, and enable simpler and more cost-effective treatment.
Among the strengths of this study, it can be highlighted that data related to OOP was collected from three sources, which is in contrast to previous studies. The data of this study provide a detailed picture of OOP. In addition, our study contained comprehensive information on socio-economic characteristics, which allows us to introduce a wide range of factors influencing OOP.
The limitations of this study included the patient's recall error in stating the costs incurred during the past year. The authors attempted to validate the patient-reported costs by comparing the costs received from the patient records from the hospital and the costs paid by the IHIO. Another limitation was under-the-table or informal costs that patients were afraid to disclose. Before asking questions related to direct and indirect OOP costs, we tried to gain the trust of patients.
5.1. Conclusions
Despite comprehensive health care and support from social and depriving organizations in Iran, OOP can be significantly high for some patients. Breast cancer patients incur many expenses, and about 32.89% of these expenses are OOP payments. In order to support BC patients, insurance organizations need to increase their coverage. Additionally, there is a need for more government support in providing the necessary medicine and medical items.